anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recommended first and second line treatments for unresectable metastatic colorectal cancer (mCRC) include fluorouracil-based chemotherapy, anti-vascular endothelial growth factor (VEGF)-based therapy, and anti-epidermal growth factor receptor-targeted therapies. In third line, the SUNLIGHT trial showed that trifluridine/tipiracil + bevacizumab (FTD/TPI + BEV) provided significant survival benefits and as such is now a recommended third line regimen in patients with refractory mCRC, irrespective of RAS mutational status and previous anti-VEGF treatment. Some patients are not candidates for intensive combination chemotherapy as first-line therapy due to age, low tumor burden, performance status and/or comorbidities. Capecitabine (CAP) + BEV is recommended in these patients. In the SOLSTICE trial, FTD/TPI + BEV as a first line regimen in patients not eligible for intensive therapy was not superior to CAP + BEV in terms of progression-free survival (PFS). However, in SOLSTICE, FTD/TPI + BEV resulted in similar PFS, overall survival, and maintenance of quality of life as CAP + BEV, with a different safety profile. FTD/TPI + BEV offers a possible first line alternative in patients for whom CAP + BEV is an unsuitable treatment. This narrative review explores and summarizes the clinical trial data on FTD/TPI + BEV.
The invention relates to compound sulfachlorpyridazine sodium powder, and specifically provides a preparation method of compound sulfachlorpyridazine sodium powder used for controlling pasteurella infection of livestock and poultry. 100 parts of the compound sulfachlorpyridazine sodium powder comprise 60 to 65 parts of sulfachlorpyridazine sodium, 2 to 4 parts of indometacin potassium, 10 to 25 parts of a suspending agent, 2 to 4 parts of a corrigent and the balance an acceptable carrier. The ingredients above are mixed and grinded so as to obtain the compound sulfachlorpyridazine sodium powder. The compound sulfachlorpyridazine sodium powder possesses accurate curative effects on pasteurellosis of a plurality of animals, and is suitable for popularization and application in livestock breeding. According to the preparation method, sulfachlorpyridazine sodium and indometacin potassium are used together, besides antisepsis and anti-inflammation effects, indometacin potassium is used as an antibacterial synergist of sulfachlorpyridazine sodium, so that synergistic effect is achieved, and pharmacological function of the main medicine is improved. Absorptivity of the compound sulfachlorpyridazine sodium powder, which can be taken orally, or mixed with feed for use, or dissolved in drinking water for use, is high; drug tolerance is difficult to be caused; the compound sulfachlorpyridazine sodium powder is safe to be used for protection, prevention and therapy in a long term. Palatability, fluidity and suspending water solubility are excellent; clinical administration methods are diverse; and the compound sulfachlorpyridazine sodium powder is convenient for clinical administration.
The present invention discloses an antiarrhythmic scorpion peptide, a preparation method and application thereof. The amino acid sequence of the active peptide is GYIRGSNGCLWGNEGCNKECKGFGYCWTWGLACWCEGLTWKSESNTCG. The method for preparing the antiarrhythmic scorpion peptide comprises the procedures of designing a PCR primer, using PCR to amplify antiarrhythmic peptide gene segments in the cDNA library of buthus martensii scorpion venom, and using an expression vector to convert the gene segments into escherichia coli for expression. The antiarrhythmic scorpion peptide is characterized in that the designed PCR upstream primer contains the enzyme cutting sites of small intestine kinase, the antiarrhythmic peptide gene segments which are amplified by PCR are converted into escherichia coli BL21 to obtain recombinant escherichia coli BL21(pGEX/BmKIM) by restriction enzyme cutting after being cloned into an expression vector pGEX-5x-1, the recombinant escherichia coli BL21(pGEX/BmKIM) is purified by the affinity columns of glutathione transferase after being induced by IPTG, the obtained fusion protein is expressed by the enzyme cutting of the small intestine kinase, and soluble antiarrhythmic peptide is obtained after the fusion protein is desalted. The present invention has effective antiarrhythmic activity, and the obtained recombinant peptide is soluble and has high yield. Therefore, the antiarrhythmic scorpion peptide can be widely used for preparing antiarrhythmic peptide medicines.
The study will require potential participants to undergo an eligibility screening with a member of the research team, followed by a period of seven days of habitual activity monitoring and 3 days of diet recording. Eligible participants will be allocated into study groups by way of minimization based on sex, age, BMI, and number of sit-to-stands performed in a minute. Participants will undertake two familiarisation sessions with strength, power, neural drive, and balance tests at least seven days apart, the first following eligibility screening and the second familiarisation session at least five days before the first main trial.

Thereafter, both groups will undertake a main trial the day before commencing 28 days of daily 150 g yoghurt supplement with the breakfast meal, with the exercise snacking group (ES) also undertaking two bouts of exercise snacking a day. The main trial will include measures of leg muscle function and neural drive, standing and single leg balance, and movement co-ordination during tasks of everyday ambulation. Participants will wear a physical activity monitor and pedometer for the seven days and record diet for three days during the last week of the intervention. The day after the intervention period, a follow-up main trial will be conducted as per the first main trial, followed by an optional qualitative interview regarding participant's experience of the trial.
Metachromatic leukodystrophy (MLD) is a neuro-metabolic disorder due to arylsulfatase A deficiency, causing demyelination of the central and peripheral nervous system. Hematopoietic cell transplantation (HCT) can provide a symptomatic and survival benefit for pre-symptomatic and early symptomatic patients by stabilizing CNS disease. This case series, however, illustrates the occurrence of severely progressive polyneuropathy shortly after HCT in two patients with late-infantile, one with late-juvenile, and one with adult MLD, leading to the inability to walk or sit without support. The patients had demyelinating polyneuropathy before HCT, performed at the ages of 2 years in the first two patients and at 14 and 23 years in the other two patients. The myeloablative conditioning regimen consisted of busulfan, fludarabine and, in one case, rituximab, with anti-thymocyte globulin, cyclosporine, steroids, and/or mycophenolate mofetil for GvHD prophylaxis. Polyneuropathy after HCT progressed parallel with tapering immunosuppression and paralleled bouts of infection and graft-versus-host disease (GvHD). Differential diagnoses included MLD progression, neurological GvHD or another (auto)inflammatory cause. Laboratory, electroneurography and pathology investigations were inconclusive. In two patients, treatment with immunomodulatory drugs led to temporary improvement, but not sustained stabilization of polyneuropathy. One patient showed recovery to pre-HCT functioning, except for a Holmes-like tremor, for which a peripheral origin cannot be excluded. One patient showed marginal response to immunosuppressive treatment and died ten months after HCT due to respiratory failure. The extensive diagnostic and therapeutic attempts highlight the challenge of characterizing and treating progressive polyneuropathy in patients with MLD shortly after HCT. We advise to consider repeat electro-neurography and possibly peripheral nerve biopsy in such patients. Nerve conduction blocks, evidence of the presence of T lymphocytes and macrophages in the neuronal and surrounding nerve tissue, and beneficial effects of immunomodulatory drugs may indicate a partially (auto)immune-mediated pathology. Polyneuropathy may cause major residual disease burden after HCT. MLD patients with progressive polyneuropathy could potentially benefit from a more intensified immunomodulatory drug regime following HCT, especially at times of immune activation.
INTRODUCTION: Obesity impairs patients' quality of life (QoL). Laparoscopic sleeve gastrectomy (LSG) is a common procedure for patients with severe obesity; however, studies reporting changes in obesity-related QoL are limited. The aim of this study was to assess changes in obesity-related QoL and food tolerance in the early postoperative period.
METHODS: We included 20 consecutive patients who underwent LSG between May 2021 and July 2023. We evaluated changes in obesity-related QoL 6 months after surgery using an obesity and weight loss QoL questionnaire (OWLQOL) and a weight related symptom measure (WRSM). Additionally, we assessed eating satisfaction and food tolerance after surgery.
RESULTS: The percentages of total weight loss and excess weight loss were 28.5% and 79.1%, respectively. OWLQOL scores and WRSM changed from 36.5 to 73.0 points and from 44.0 to 15.0 points (p = .007, .007), respectively. The food tolerance score decreased from 25 to 21.2 points (p < .001), while eating satisfaction showed no significant change (p = .25).
CONCLUSION: Obesity-related QoL is enhanced even in the early postoperative period, without sacrificing eating satisfaction. The findings of this study may provide valuable insights for patients when considering LSG.
1,233,876. Preservation of organic material. FARBENFABRIKEN BAYER A.G. 26 Feb., 1970 [27 Feb., 1969], No. 9384/70. Heading A2D. Organs, tissues and foodstuffs are preserved from deterioration by contact with a biological protease inhibitor. The inhibitor may be utilised in solution, and the organs, tissues or foodstuffs may be stored in or injected with the solution, or the solution may flow through an organ. The inhibitor may alternatively be utilised in the solid state, optionally in admixture with a carrier substance. A kallikreintrypsin inhibitor, or an inhibitor of vegetable i.e. potato origin, may be used. Examples describe the preservation of kidney, liver tissue and bone marrow.
AIMS: We sought to characterize circulating protein biomarkers associated with cardiogenic shock (CS) using highly multiplex proteomic profiling.
METHODS AND RESULTS: This analysis employed a cross-sectional case-control study design using a biorepository of patients admitted to a cardiac intensive care unit between 2017 and 2020. Cases were patients adjudicated to have CS, and controls were those presenting for cardiac critical care without shock, including subsets of patients with isolated hypotension or heart failure (HF). The Olink platform was used to analyse 359 biomarkers with Bonferroni correction. The analysis included 239 patients presenting for cardiac critical care (69 cases with CS, 170 non-shock controls). A total of 63 biomarkers (17.7%) were significantly associated with CS after Bonferroni correction compared with all controls. Of these, nine biomarkers remained significantly associated with CS when separately cross-validated in subsets of controls presenting with isolated hypotension and HF: cathepsin D, fibroblast growth factor (FGF)-21 and -23, growth differentiation factor (GDF)-15, insulin-like growth factor-binding protein-1, N-terminal pro-B-type natriuretic peptide, osteopontin, oncostatin-M-specific receptor subunit beta (OSMR), and soluble ST2 protein (sST2). Four biomarkers were identified as providing complementary information for CS diagnosis with development of a multi-marker model: sST2, FGF-23, CTSD, and GDF-15.
CONCLUSION: In this pilot study of targeted proteomic profiling in CS, we identified nine biomarkers significantly associated with CS when cross-validated against non-shock controls including those with HF or isolated hypotension, illustrating the potential application of a targeted proteomic approach to identify novel candidates that may support the diagnosis of CS.
Healthy non-pregnant girls 9-17 years of age received a single dose of RSV MAT vaccine at Day 1 and were scheduled to receive a single dose of dTpa vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration). Participants who were enrolled and were due to receive the dTpa vaccine at Day 31, did no longer receive the dTpa as part of this study, but they were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.
It is estimated that grass pollen is responsible for 10 - 30% of all IgE-mediated allergies worldwide 1. Temperate grasses, including Dactylis glomerata (Orchard Grass), Lolium perenne (Rye Grass), Phleum pratense (Timothy Grass) and Poa pratensis (Blue Grass), have practically identical allergenic characteristics. Subtropical grasses, such as Cynodon dactylon (Bermuda Grass), are antigenically distinct from temperate grasses and should be regarded as separate allergenic sources. For effective testing and treatment with grass pollen extracts, the extracts must be properly selected to represent the allergenic enviornment of the allergic individual 1,2,3,4. 

Grass pollen extract may have as many as 40 components, of which 5 - 10 may be allergenic. The most important allergens are classified into groups I - VI. Allergens in these groups account for 90 - 100% of the IgE binding prevalence in the serum of grass pollen allergenic patients 1,5. 

The pharmacologic action of grass pollen extract used diagnostically is based on the liberation of histamine and other substances when allergens in the extract react with specific IgE antibody attached to mast cells. The release of pharmacologically active mediators from mast cell results in the wheal-flare reaction associated with a positive skin test 6,7. 

The basis for the clinical improvement of allergic symptoms following immunotherapy with grass pollen extract is not clearly understood. Several immunologic changes have been demonstrated that might be responsible for the amelioration of allergenic symptoms. These changes include (a) increase in serum IgG antbodies, (b) blunting of the seasonal rise of IgE antibodies, (c) elevation of blocking IgA/IgG antibodies in secretions, (d) reduced basophil reactivity and sensitivity to allergens and (e) reduced in vitro lymphocyte responsiveness to allergens 8. There is evidence that symptoms are effectively altered only by the administration of the relevant allergen 9,10,11. 

The results shown in Table 1 were observed with 10,000 BAU/mL reference extract administered to 15 highly sensitive grass allergic persons by the puncture method (data on file at FDA). The intradermal doses (BAU/mL) of grass pollen extracts required to elicit 50 mm sum of erythema are shown in Table 2 12. 

Note: Relative potency compared to the U.S. Reference with potency of 1.0. The U.S. Reference for Bermuda Grass is 10,000 BAU/mL (range:6,900 - 143,000 BAU/mL). The U.S Reference for other grasses are 100,000 BAU/mL (range: 69,000 - 143,000 BAU/mL).
Reversible Cerebral Vasoconstriction Syndrome clinically presents as severe headaches with or without neurological deficits accompanied by multilocal caliber variation of the cerebral arteries on imaging studies. Transient Global Amnesia is a benign neurological condition that implies sudden temporary antero- and retrograde amnesia. The exact pathophysiological mechanisms involved in transient global amnesia and reversible cerebral vasoconstriction syndrome remain unclear but suggest similar pathways as both can be triggered by factors that activate the sympathetic nervous system. We herein discuss a potential relationship of the two conditions in a 65-year-old woman that initially presented herself to the emergency department with temporary memory impairment, indicating Transient Global Amnesia. Four days later, the patient revealed a thunderclap headache accompanied by a subarachnoid hemorrhage with transient segmental narrowing of the arteries of the anterior circulation on neuroimaging. In this case report we hypothesize that Reversible Cerebral Vasoconstriction Syndrome might be a potential cause for the clinical symptoms and imaging patterns with Transient Global Amnesia as a possible prodromal stage of Reversible Cerebral Vasoconstriction Syndrome.
FIELD: medicine. SUBSTANCE: method involves carrying out deintoxication, hemorrhage stopping antibacterial and generally strengthening therapy. Then, combine chemotherapy and radiotherapy are applied on the prednisolone background. 5-fluorouracyl is used as napkins. Radiation therapy is carried out in the medium dose fractioning at a dose of 3 Gr daily at the mammary gland base until total dose of 45 Gr is not achieved. The dose is equal to 33- 36 Gr when applied to regional lymph discharge zone. After the treatment being over, 2-3 weeks later, traditional chemotherapy is administered according to one of commonly used schemes. EFFECT: enhanced effectiveness of treatment; prolonged remission period. 3 cl
Five general types of evaluations will be employed over multiple study sessions at the National Center for Rehabilitative Auditory Research (NCRAR). First, a neurologist will review the subject's medical history and perform a neurologic exam to confirm MS diagnosis. Second, peripheral auditory function will be evaluated using a standard set of routine audiometric tests. Additionally, subjects will complete a case history and series of hearing handicap inventories. Third, a battery of behavioral procedures will be used to characterize central auditory processing. Fourth, auditory evoked potential studies will be performed. Emphasis here will be upon evoked potentials whose putative neural generators lie within the central auditory nervous system. Fifth, subjects will receive magnetic resonance imaging (MRI) evaluation to determine sites and amount of neural degeneration.
Neuroplastic changes appear in people with visual impairment (VI) and they show greater tactile abilities. Improvements in performance could be associated with the development of enhanced early attentional processes based on neuroplasticity. Currently, the various early attentional and cortical remapping strategies that are utilized by people with early (EB) and late-onset blindness (LB) remain unclear. Thus, more research is required to develop effective rehabilitation programs and substitution devices. Our objective was to explore the differences in spatial tactile brain processing in adults with EB, LB and a sighted control group (CG). In this cross-sectional study 27 participants with VI were categorized into EB (n = 14) and LB (n = 13) groups. They were then compared with a CG (n = 15). A vibrotactile device and event-related potentials (ERPs) were utilized while participants performed a spatial tactile line recognition task. The P100 latency and cortical areas of maximal activity were analyzed during the task. The three groups had no statistical differences in P100 latency (p>0.05). All subjects showed significant activation in the right superior frontal areas. Only individuals with VI activated the left superior frontal regions. In EB subjects, a higher activation was found in the mid-frontal and occipital areas. A higher activation of the mid-frontal, anterior cingulate cortex and orbitofrontal zones was observed in LB participants. Compared to the CG, LB individuals showed greater activity in the left orbitofrontal zone, while EB exhibited greater activity in the right superior parietal cortex. The EB had greater activity in the left orbitofrontal region compared to the LB. People with VI may not have faster early attentional processing. EB subjects activate the occipital lobe and right superior parietal cortex during tactile stimulation because of an early lack of visual stimuli and a multimodal information processing. In individuals with LB and EB the orbitofrontal area is activated, suggesting greater emotional processing.
A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
The invention relates to an aspirin enteric-coated preparation prepared by a solvent-free extrusion spheronization method. The aspirin enteric-coated preparation comprises the following components: drug-containing pills, contagion gown and enteric coating, wherein the drug-containing pills contains 5 to 8.5 parts of aspirin, 1.5 to 5 parts of lipid matrix and 0 to 1 part of release regulator in parts by weight; and the weight of increment of contagion gown accounts for 1-8% of that of the drug-containing pills, and the weight of increment of contagion gown accounts for 5 to 30% of that of the contagion gown pills. The preparation method is as follows in sequence: utilizing an extrusion spheronization method to prepare the drug-containing pills without the absence of water, preparing the contagion gown and the enteric coating, and then filling capsules. A lipin material is utilized as an adhesive and a filling diluent, and the prepared aspirin enteric-coated preparation has good sensitive stability and large drug-loading rate. The in-vitro releasing results of enteric-coated micro-pills show that almost no enteric-coated micro-pills release in a medium with pH of 1.2, while more than 70% of the enteric-coated micro-pills release in 45min in phosphate buffer medium with pH of 6.8, which shows significant enteric-coated characteristics; in-vivo studies of Beagle dogs show that compared with commercially available enteric-coated tablets, the relative bioavailability of the invention is 125.7%. The in-vitro slow-releasing results of enteric-coated micro-pills show that almost no enteric-coated micro-pills release in a medium with pH of 1.2, while significant slow-releasing effect is obtained in phosphate buffer medium with pH of 6.8, and the quality of pills is stable; and in-vivo pharmacokinetic studies of Beagle dogs show that compared with commercially available aspirin slow-releasing enteric-coated tablets, the relative bioavailability of the invention is 112.9%.
Patients receive aspirin PO daily for 12 weeks in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial.